The mutation of EZH2 in B-cell lymphomas motivated the development of small-molecule inhibitors that act as SAM-competitive binders of the SET domain and exhibit high selectivity for EZH1/2 (Helin and Dhanak 2013; Kim and Roberts 2016). Here, EZH2 is linked to B-cell non-Hodgkin lymphoma.